ChromaCode Adds Industry Leaders, Pat Balthrop And Kevin O’Boyle, To Board Of Directors

ChromaCode, Inc., a company that combines data science and proprietary reagents to improve clinical molecular analysis, announced that Patrick Balthrop, Sr. and Kevin O’Boyle have joined the company’s Board of Directors.

Recommended AI News: Mediaocean Completes Integration Of Cloud-Based Media Finance Solutions With Microsoft Dynamics 365

Mr. Balthrop is the former CEO and President of Luminex, a pioneer in multiplexed diagnostics platform development; chairman of the Board at Agendia, Inc, a molecular diagnostic company focused on oncology diagnostics for breast cancer; chairman of Discovery Life Sciences, a world leader in biospecimen and biomarker services; and a founding principal of Apalachee Ventures, LLC.

Mr. O’Boyle was most recently Chairman of the Board of Directors at GenMark Diagnostics, a leading provider of sample-to-answer molecular diagnostic solutions acquired by Roche in March, 2021; and is currently a member of the Board of Directors at Nevro and Sientra.

“We are expanding the Board to include long-tenured leadership in our targeted markets,” said ChromaCode’s CEO and co-founder, Greg Gosch. “Pat’s and Kevin’s breadth of expertise will be invaluable as we expand our footprint in oncology, reproductive health and infectious disease using our HDPCR™ technology.”

Alex Dickinson, ChromaCode’s Executive Chairman and co-founder commented, “We are very fortunate to welcome Pat and Kevin to the board and look forward to benefiting from their vast experience in molecular diagnostics. Their expertise adds a wealth of industry know-how and will support execution of our long-term strategy.”

Recommended AI News: Graystone Company Forecasted Revenue From Bitcoin Mining Operation